

Accepted Manuscript

Title: Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)

Author: C.I. Edvard Smith

PII: S1044-579X(16)30077-3

DOI: <http://dx.doi.org/doi:10.1016/j.semcancer.2016.11.008>

Reference: YSCBI 1278

To appear in: *Seminars in Cancer Biology*

Received date: 26-8-2016

Accepted date: 9-11-2016



Please cite this article as: Smith C.I.Edvard.Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).*Seminars in Cancer Biology* <http://dx.doi.org/10.1016/j.semcancer.2016.11.008>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)

C. I. Edvard Smith
Clinical Research Center
Dept. of laboratory medicine
Karolinska Institutet
Karolinska University Hospital Huddinge
SE-14186 Huddinge
Sweden

Correspondence:

C. I. Edvard Smith
Clinical Research Center
Dept. of laboratory medicine
Karolinska Institutet
Karolinska University Hospital Huddinge
SE-14186 Huddinge
Sweden

email: edvard.smith@ki.se

Keywords:

Acalabrutinib, alectinib, brigatinib, ceritinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, ibrutinib, imatinib, lorlatinib, nilotinib, osimertinib, rociletinib, trametinib, vemurafenib

Download English Version:

<https://daneshyari.com/en/article/8361869>

Download Persian Version:

<https://daneshyari.com/article/8361869>

[Daneshyari.com](https://daneshyari.com)